Aquinox Pharmaceuticals (AQXP) Now Covered by Analysts at Guggenheim

Guggenheim began coverage on shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) in a research report released on Thursday morning, MarketBeat.com reports. The firm issued a buy rating and a $26.00 price objective on the stock.

Several other analysts have also weighed in on AQXP. Cantor Fitzgerald restated a buy rating and issued a $28.00 price objective on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Needham & Company LLC restated a buy rating and issued a $25.00 price objective on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Canaccord Genuity restated a buy rating and issued a $22.00 price objective on shares of Aquinox Pharmaceuticals in a report on Tuesday, November 21st. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a hold rating to a buy rating and set a $13.00 price objective for the company in a report on Tuesday, January 9th. Finally, BidaskClub upgraded Aquinox Pharmaceuticals from a strong sell rating to a sell rating in a report on Monday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $22.80.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded up $2.08 during trading on Thursday, hitting $15.48. The stock had a trading volume of 292,624 shares, compared to its average volume of 97,370. Aquinox Pharmaceuticals has a twelve month low of $10.02 and a twelve month high of $19.97.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.12. analysts forecast that Aquinox Pharmaceuticals will post -2.08 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. raised its position in shares of Aquinox Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock worth $4,010,000 after purchasing an additional 5,046 shares during the period. Vanguard Group Inc. raised its position in shares of Aquinox Pharmaceuticals by 6.6% during the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after purchasing an additional 17,455 shares during the period. University of Notre Dame DU Lac raised its position in shares of Aquinox Pharmaceuticals by 11.1% during the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock worth $2,700,000 after purchasing an additional 19,066 shares during the period. Northern Trust Corp raised its position in shares of Aquinox Pharmaceuticals by 3.3% during the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after purchasing an additional 2,691 shares during the period. Finally, Sphera Funds Management LTD. raised its position in shares of Aquinox Pharmaceuticals by 21.7% during the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock worth $1,072,000 after purchasing an additional 13,450 shares during the period. 96.26% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/09/aquinox-pharmaceuticals-aqxp-now-covered-by-analysts-at-guggenheim.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply